Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2023-09-13 00:00:00 ET · period of report 2023-09-12 · accession 0001209191-23-049357 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-13 | 2023-09-12 | DYN | Brumm Joshua T | See Remarks, Dir | S - Sale | $10.41 | -7,672 | 245.7K | -3% | -$79.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-12 | S | D | 7,672 | $10.41 | 245,711 | D | — | — | (F1) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.09 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. (F3) Includes 236,996 unvested RSUs. |